Stuart Pocock
#27,285
Most Influential Person Now
British medical statistician
Stuart Pocock's AcademicInfluence.com Rankings
Stuart Pocockmathematics Degrees
Mathematics
#1697
World Rank
#2722
Historical Rank
Statistics
#52
World Rank
#74
Historical Rank
Measure Theory
#67
World Rank
#109
Historical Rank
Download Badge
Mathematics
Why Is Stuart Pocock Influential?
(Suggest an Edit or Addition)According to Wikipedia, Stuart J. Pocock is a British medical statistician. He has been professor of medical statistics at the London School of Hygiene and Tropical Medicine since 1989. His research interests include statistical methods for the design, monitoring, analysis and reporting of randomized clinical trials. He also collaborates on major clinical trials, particularly in cardiovascular disease.
Stuart Pocock's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. (2007) (18663)
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies (2007) (7183)
- Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. (2010) (6019)
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies (2007) (6009)
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. (2008) (5931)
- Transcatheter versus surgical aortic-valve replacement in high-risk patients. (2011) (5212)
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007) (4141)
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. (2014) (3753)
- Epidemiologic Research: Principles and Quantitative Methods. (1983) (3482)
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (2016) (2621)
- Eplerenone in patients with systolic heart failure and mild symptoms. (2011) (2505)
- Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients (2019) (2461)
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies (2007) (2358)
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies (2007) (2298)
- Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. (1975) (2086)
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. (2020) (1835)
- Bivalirudin during primary PCI in acute myocardial infarction. (2008) (1816)
- [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. (2007) (1810)
- Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. (2007) (1694)
- A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting (1998) (1635)
- Clinical Trials: A Practical Approach (1984) (1634)
- Group sequential methods in the design and analysis of clinical trials (1977) (1593)
- Ferric carboxymaltose in patients with heart failure and iron deficiency. (2009) (1586)
- Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. (2006) (1505)
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007) (1422)
- A factorial trial of six interventions for the prevention of postoperative nausea and vomiting* (2004) (1380)
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial (2009) (1317)
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. (2007) (1310)
- Explanation and Elaboration (1282)
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. (2007) (1260)
- Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials (2000) (1189)
- Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. (2012) (1186)
- Bivalirudin for patients with acute coronary syndromes. (2006) (1122)
- Subgroup analysis and other (mis)uses of baseline data in clinical trials (2000) (1096)
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction. (2021) (1081)
- Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems (2002) (1003)
- 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). (2014) (983)
- Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. (2007) (939)
- Guidelines for Reporting Observational Studies (2007) (892)
- Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. (2007) (887)
- Predictors of mortality and morbidity in patients with chronic heart failure. (2006) (882)
- 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). (2014) (880)
- Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. (2006) (873)
- Incidence (1931) (868)
- Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure (2006) (859)
- Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. (2016) (832)
- Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. (2013) (812)
- Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. (2007) (800)
- Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. (2016) (769)
- Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. (2012) (744)
- Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials (2009) (730)
- Statistical guidelines for contributors to medical journals. (1983) (729)
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. (2008) (688)
- Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients (2005) (686)
- A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. (1999) (676)
- Strategy for intention to treat analysis in randomised trials with missing outcome data (2011) (672)
- Statistical problems in the reporting of clinical trials. A survey of three medical journals. (1987) (652)
- A risk score to predict bleeding in patients with acute coronary syndromes. (2010) (640)
- Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. (2015) (638)
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials (2020) (599)
- Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial (2002) (582)
- [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. (2007) (581)
- British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. (1981) (566)
- Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. (2010) (544)
- Ticagrelor with or without Aspirin in High-Risk Patients after PCI. (2019) (539)
- Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. (1992) (537)
- Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure (2007) (535)
- Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study (2013) (532)
- Randomized trials or observational tribulations? (2000) (531)
- The analysis of multiple endpoints in clinical trials. (1987) (512)
- Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial (2004) (508)
- Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial (2017) (503)
- Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial (2018) (486)
- Can meta-analyses be trusted? (1991) (482)
- Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. (2004) (477)
- Bivalirudin started during emergency transport for primary PCI. (2013) (473)
- Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial (2011) (458)
- Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. (2009) (455)
- Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials (2015) (436)
- Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls (2002) (424)
- Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes (2006) (418)
- Environmental lead and children's intelligence: a systematic review of the epidemiological evidence (1994) (415)
- Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. (1992) (411)
- Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. (2016) (410)
- Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial (2009) (408)
- Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. (2016) (406)
- Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. (2019) (393)
- Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial (2007) (392)
- Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. (2003) (384)
- Effect of Antihypertensive Drug Treatment on Cardiovascular Outcomes in Women and Men (1997) (380)
- Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (2011) (356)
- The combination of randomized and historical controls in clinical trials. (1976) (355)
- Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. (2015) (349)
- Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. (2009) (344)
- BMI and risk of dementia in two million people over two decades: a retrospective cohort study. (2015) (338)
- Body Mass Index and Prognosis in Patients With Chronic Heart Failure: Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program (2007) (336)
- The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities (2011) (331)
- Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program (2009) (328)
- Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) (2005) (325)
- Issues in the reporting of epidemiological studies: a survey of recent practice (2004) (319)
- Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. (2015) (306)
- Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study (2015) (304)
- Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. (2007) (304)
- A proposal for structured reporting of randomized controlled trials. The Standards of Reporting Trials Group. (1994) (299)
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention (2019) (293)
- Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis (2018) (289)
- J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data (2002) (286)
- Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial (2020) (280)
- A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials (2001) (271)
- Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. (1985) (270)
- Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. (2007) (267)
- Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk (2019) (266)
- Reporting of Noninferiority and Equivalence Randomized Trials (2013) (264)
- Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. (2007) (260)
- SOCIAL CLASS DIFFERENCES IN ISCHAEMIC HEART DISEASE IN BRITISH MEN (1987) (259)
- Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program (2006) (257)
- Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program (2004) (256)
- Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial (2018) (252)
- Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. (1980) (252)
- Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting (1998) (251)
- Adaptive increase in sample size when interim results are promising: A practical guide with examples (2011) (241)
- Interim analyses for randomized clinical trials: the group sequential approach. (1982) (241)
- Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. (1997) (240)
- Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program (2007) (239)
- Effect of Early Metoprolol on Infarct Size in ST-Segment–Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) Trial (2013) (237)
- Issues in data monitoring and interim analysis of trials. (2005) (237)
- A proposed charter for clinical trial data monitoring committees: helping them to do their job well (2005) (234)
- Maternal vitamin D intake and mineral metabolism in mothers and their newborn infants. (1980) (234)
- Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations (2012) (234)
- A polypill strategy to improve adherence: results from the FOCUS project. (2014) (232)
- Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial (2010) (231)
- Risk factors for stroke in middle aged British men. (1991) (229)
- A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) (2019) (226)
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2009) (222)
- Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial (2020) (217)
- Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. (2017) (213)
- Risks to healthcare workers following tracheal intubation of patients with COVID‐19: a prospective international multicentre cohort study (2020) (211)
- Long-term survival of patients with breast cancer: a study of the curability of the disease. (1979) (209)
- Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. (1987) (208)
- Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review (2017) (204)
- Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). (2013) (201)
- When to stop a clinical trial. (1992) (200)
- Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. (2013) (200)
- The Primary Outcome Fails - What Next? (2016) (199)
- Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. (2009) (193)
- Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. (2005) (186)
- Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. (2019) (183)
- Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document (2013) (183)
- Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery. (2002) (182)
- Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved (2014) (181)
- Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. (1997) (177)
- A polypill strategy to improve adherence: results from FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project (2014) (174)
- Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L‐phenylalanine mustard (1976) (171)
- Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. (2008) (170)
- Can We Improve the Statistical Analysis of Stroke Trials?: Statistical Reanalysis of Functional Outcomes in Stroke Trials (2007) (169)
- British Regional Heart Study: geographic variations in cardiovascular mortality, and the role of water quality (1980) (166)
- Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. (2008) (166)
- Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. (1989) (162)
- Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial‡☆ (2000) (160)
- Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups (2002) (159)
- When (not) to stop a clinical trial for benefit. (2005) (158)
- Regression of area mortality rates on explanatory variables: what weighting is appropriate? (1981) (157)
- The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data (2014) (155)
- Insulin glargine and malignancy: an unwarranted alarm (2009) (154)
- Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). (2014) (152)
- Practical problems in interim analyses, with particular regard to estimation. (1989) (151)
- Short-term effects of air pollution on daily mortality in Athens: a time-series analysis. (1994) (150)
- Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status (2020) (150)
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial (2020) (148)
- The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors (2017) (144)
- GIVING UP SMOKING AND THE RISK OF HEART ATTACKS A report from The British Regional Heart Study (1986) (143)
- Regression Models and Non‐Proportional Hazards in the Analysis of Breast Cancer Survival (1984) (142)
- Multiple regression in geographical mortality studies, with allowance for spatially correlated errors. (1983) (142)
- Mortality of shift and day workers 1956-68 (1972) (141)
- Identifying men at high risk of heart attacks: strategy for use in general practice. (1986) (141)
- Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol (2005) (140)
- Diurnal variations in serum biochemical and haematological measurements. (1989) (134)
- Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program) (2018) (133)
- Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial (2010) (131)
- Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. (2011) (131)
- Effects of alcohol and smoking on blood lead in middle-aged British men. (1982) (130)
- Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department: A Cohort Study. (2017) (128)
- The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. (2016) (127)
- Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients (2005) (125)
- Wheeze associated with prenatal tobacco smoke exposure: a prospective, longitudinal study (2000) (124)
- High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men. (1986) (124)
- The pros and cons of noninferiority trials (2003) (123)
- Feasibility and exploratory efficacy evaluation of the Embrella Embolic Deflector system for the prevention of cerebral emboli in patients undergoing transcatheter aortic valve replacement: the PROTAVI-C pilot study. (2014) (121)
- Allocation of patients to treatment in clinical trials. (1979) (120)
- Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Significantly Reduces Death and Stroke Compared With Unprotected Procedures. (2017) (120)
- Biochemical and Haematological Response to Alcohol Intake (1985) (119)
- The agonising negative trend in monitoring of clinical trials (1999) (119)
- An epidemiological study of workers producing enzyme washing powders. (1970) (118)
- Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). (2005) (116)
- Stopping rules and estimation problems in clinical trials. (1988) (114)
- Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia (2009) (114)
- The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study (2009) (113)
- Long term survival analysis: the curability of breast cancer. (1982) (112)
- Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study. (1991) (110)
- The relationship between blood lead, blood pressure, stroke, and heart attacks in middle-aged British men. (1988) (110)
- On the design and analysis of randomized clinical trials with multiple endpoints. (1993) (108)
- Trials stopped early: too good to be true? (1999) (108)
- Blood lead concentration, blood pressure, and renal function. (1984) (108)
- Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). (2014) (107)
- Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials (2011) (107)
- Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. (2020) (105)
- The Primary Outcome Is Positive - Is That Good Enough? (2016) (104)
- Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial (2017) (104)
- Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. (2016) (103)
- 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents. (2017) (103)
- [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. (2008) (103)
- Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. (2009) (102)
- Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. (2015) (102)
- Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. (2004) (101)
- Long-Term Cardiovascular Mortality After Procedure-Related or Spontaneous Myocardial Infarction in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome: A Collaborative Analysis of Individual Patient Data From the FRISC II, ICTUS, and RITA-3 Trials (FIR) (2012) (100)
- Categorisation of continuous risk factors in epidemiological publications: a survey of current practice (2010) (99)
- Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction (2020) (98)
- Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial (2019) (96)
- Coping with missing data in clinical trials: A model‐based approach applied to asthma trials (2002) (95)
- Lead Exposure and Child Development: An International Assessment (1989) (95)
- Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. (2019) (94)
- Rosiglitazone RECORD study: glucose control outcomes at 18 months (2007) (88)
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function (2020) (87)
- A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial (1996) (87)
- Effects of tap water lead, water hardness, alcohol, and cigarettes on blood lead concentrations. (1983) (87)
- Estimation issues in clinical trials and overviews. (1990) (86)
- Current issues in the design and interpretation of clinical trials. (1985) (85)
- Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial (2021) (83)
- Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2008) (83)
- Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. (2008) (83)
- 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA) (2014) (83)
- Current controversies in data monitoring for clinical trials (2006) (83)
- The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial (2014) (82)
- Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome patients) study (2015) (81)
- Neonatal head circumference, neonatal weight, and risk of hayfever, asthma and eczema in a large cohort of adolescents from Sheffield, England (2003) (81)
- Das Strengthening the Reporting of Observational Studies in Epidemiology (STROBE-) Statement (2008) (80)
- Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. (2017) (80)
- Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS‐HF trial (2017) (80)
- Diagnostic and Prognostic Implications of Coronary Flow Capacity: A Comprehensive Cross-Modality Physiological Concept in Ischemic Heart Disease. (2015) (80)
- Statistical Aspects of Clinical Trial Design (1982) (79)
- The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology (2014) (79)
- Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. (2012) (78)
- Effect of Early Metoprolol on Infarct Size in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary PCI: The METOCARD-CNIC Trial (2013) (78)
- Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. (2020) (77)
- Lead exposure and children's intellectual performance. (1987) (77)
- The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. (2013) (75)
- INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results. (1995) (74)
- Estimation and comparison of rates of change in longitudinal studies with informative drop-outs. (1999) (74)
- Size of cancer clinical trials and stopping rules. (1978) (73)
- The hope and the hazards of using compliance data in randomized controlled trials. (1998) (73)
- Some Studies of Maternal and Infant Lead Exposure in Glasgow (1982) (72)
- The variability of serum cholesterol measurements: implications for screening and monitoring. (1990) (72)
- Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial (2021) (71)
- Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. (2021) (71)
- Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. (2000) (71)
- Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. (2009) (71)
- Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials. (2015) (70)
- Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial (2020) (70)
- Statistical and ethical issues in monitoring clinical trials. (1993) (70)
- Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme (2010) (69)
- Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. (2019) (68)
- Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). (2014) (68)
- Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. (2015) (68)
- Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial (2018) (68)
- Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme (2007) (66)
- Ticagrelor With or Without Aspirin After Complex PCI (2020) (66)
- An international multicenter protocol to assess the single and combined benefits of antiemetic interventions in a controlled clinical trial of a 2x2x2x2x2x2 factorial design (IMPACT). (2003) (66)
- Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. (2004) (66)
- CONTRIBUTION OF LEAD IN DRINKING WATER TO BLOOD-LEAD (1977) (65)
- Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. (2020) (65)
- Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. (2021) (64)
- An Extension of the CONSORT Statement (2006) (64)
- Impact of Missing Data Due to Selective Dropouts in Cohort Studies and Clinical Trials (2002) (64)
- Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study (2016) (63)
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial (2020) (62)
- Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. (2013) (62)
- Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF) (2012) (62)
- Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. (2016) (61)
- Randomised clinical trials. (1977) (61)
- Sex‐related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study (2017) (60)
- A perspective on the role of quality-of-life assessment in clinical trials. (1991) (60)
- Translating statistical findings into plain English (2009) (60)
- Short Telomere Load, Telomere Length, and Subclinical Atherosclerosis: The PESA Study. (2016) (59)
- 10-Year Mortality Outcome of a Routine Invasive Strategy Versus a Selective Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome: The British Heart Foundation RITA-3 Randomized Trial. (2015) (59)
- Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme (2006) (59)
- Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. (2020) (59)
- Predicting Subclinical Atherosclerosis in Low-Risk Individuals: Ideal Cardiovascular Health Score and Fuster-BEWAT Score. (2017) (58)
- Influenza Vaccination after Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. (2021) (58)
- Commuter travel and sickness absence of London office workers. (1972) (58)
- Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. (2021) (58)
- Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. (2019) (57)
- Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. (2015) (57)
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction (2021) (57)
- The Size of a Clinical Trial (2013) (56)
- The perils of surrogate endpoints. (2015) (56)
- Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial (2021) (56)
- Coronary angioplasty versus medical therapy for angina. Health service costs based on the second Randomized Intervention Treatment of Angina (RITA-2) trial. (2002) (54)
- Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials. (2015) (54)
- Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial (2019) (54)
- Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). (2012) (53)
- Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (53)
- Impact of missing data due to drop‐outs on estimators for rates of change in longitudinal studies: a simulation study (2001) (53)
- The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial (2007) (53)
- Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials (2018) (52)
- Blood lead and blood pressure. (1985) (52)
- Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials (2018) (51)
- International differences in treatment effect: do they really exist and why? (2013) (51)
- Do current clinical trials meet society's needs?: a critical review of recent evidence. (2014) (51)
- Identification of risk factors in hypertensive patients: contribution of randomized controlled trials through an individual patient database. (1999) (51)
- Linearly divergent treatment effects in clinical trials with repeated measures: efficient analysis using summary statistics. (1997) (50)
- Empagliflozin and Major Renal Outcomes in Heart Failure. (2021) (50)
- Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
- Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot ‘Prevention of Decline in Cognition after Stroke Trial’ (PODCAST) Randomised Controlled Trial (2017) (49)
- The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study (2011) (49)
- The simplest statistical test: how to check for a difference between treatments (2006) (49)
- Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns (2016) (48)
- Contribution of cardiac and extra‐cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure (2018) (48)
- Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial (2021) (48)
- Prognosis of patients with acute myocardial infarction admitted to a coronary care unit. I: Survival in hospital. (1977) (48)
- Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials. (2015) (48)
- International patterns of dual antiplatelet therapy duration after acute coronary syndromes (2016) (48)
- Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. (2016) (47)
- A method to measure the adsorption of bile salts to vegetable fiber of differing water holding capacity. (1976) (47)
- The effect of age on outcomes of coronary artery bypass surgery compared with balloon angioplasty or bare-metal stent implantation among patients with multivessel coronary disease. A collaborative analysis of individual patient data from 10 randomized trials. (2012) (47)
- Analysing geographic variation in cardiovascular mortality: methods and results. (1982) (47)
- Prognosis of patients with acute myocardial infarction admitted to a coronary care unit. II. Survival after hospital discharge. (1977) (47)
- Ticagrelor with or without Aspirin in High-Risk Patients with Diabetes Mellitus undergoing Percutaneous Coronary Intervention. (2020) (47)
- Alcohol and ischaemic heart disease in middle aged British men. (1987) (46)
- Use of Ordinal Outcomes in Vascular Prevention Trials: Comparison With Binary Outcomes in Published Trials (2008) (46)
- Long‐term survival in patients with advanced immunodeficiency (1997) (46)
- Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Gastro-Intestinal Therapeutic System. (1998) (46)
- Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. (2019) (46)
- A scoring system to identify men at high risk of a heart attack. (1987) (45)
- Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials. (2015) (45)
- A win ratio approach to comparing continuous non‐normal outcomes in clinical trials (2016) (45)
- Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model (2016) (45)
- Detection and Estimation of J-shaped Risk-Response Relationships (1995) (44)
- Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. (2017) (44)
- Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. (2017) (44)
- Randomized trials, statistics, and clinical inference. (2010) (44)
- Studies of water quality and cardiovascular disease in the United Kingdom. (1981) (43)
- Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial. (2018) (43)
- Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial (2022) (43)
- Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient‐level database analysis (2020) (43)
- Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial (2019) (42)
- Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. (2016) (42)
- The Program SI! intervention for enhancing a healthy lifestyle in preschoolers: first results from a cluster randomized trial (2013) (42)
- Parental death from heart disease and the risk of heart attack. (1988) (42)
- Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors (2017) (41)
- Changes in Plasma Renin Activity after Renal Artery Sympathetic Denervation. (2021) (41)
- Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany (2017) (40)
- The impact of stopping rules on heterogeneity of results in overviews of clinical trials. (1992) (40)
- A cluster randomized trial to evaluate the efficacy of a school-based behavioral intervention for health promotion among children aged 3 to 5 (2013) (40)
- Predicting two-year mortality from discharge after acute coronary syndrome: An internationally-based risk score (2019) (40)
- Factorial trials in cardiology: pros and cons. (1994) (40)
- Ticagrelor With Aspirin or Alone After Complex PCI: The TWILIGHT-COMPLEX Analysis. (2020) (39)
- Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. (2017) (39)
- Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial (2016) (39)
- Ordered Polytomous Regression: An Example Relating Serum Biochemistry and Haematology to Alcohol Consumption (1986) (39)
- Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink (2018) (38)
- Figures in clinical trial reports: current practice & scope for improvement (2007) (37)
- Blood pressure and hypertension in middle-aged British men. (1988) (37)
- Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study) (2008) (37)
- Plasma cholesterol, coronary heart disease, and cancer (1989) (37)
- Absenteeism of shift and day workers: A study of six types of shift system in 29 organizations (1972) (37)
- Assessing treatment-time interaction in clinical trials with time to event data: a meta-analysis of hypertension trials. (1998) (36)
- Practical experience of randomization in cancer trials: an international survey. (1982) (36)
- Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week. (2019) (36)
- Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction (2013) (36)
- The data monitoring experience in the MOXCON trial. (2004) (36)
- [2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment andmanagement]. (2014) (36)
- Differences in physical characteristics, perinatal histories, and social backgrounds between children with growth hormone deficiency and constitutional short stature. (1981) (35)
- Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study (2013) (35)
- Glyceryl Trinitrate for Acute Intracerebral Hemorrhage: Results From the Efficacy of Nitric Oxide in Stroke (ENOS) Trial, a Subgroup Analysis (2016) (34)
- Learning from recent trials and shaping the future of acute heart failure trials. (2013) (34)
- Factors influencing household water lead: a British national survey. (1980) (33)
- Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. (2016) (33)
- Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. (2020) (33)
- Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. (2021) (33)
- Association Between a Social-Business Eating Pattern and Early Asymptomatic Atherosclerosis. (2016) (33)
- Statistical reporting of clinical trials with individual changes from allocated treatment. (1996) (33)
- Time Trends in Serum Cholesterol before Cancer Death (1997) (32)
- Variation in the incidence of diverticular disease within the city of Edinburgh. (1977) (32)
- Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. (2021) (32)
- Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition. (2021) (32)
- Prediction of short-term survival with an application in primary biliary cirrhosis. (1992) (32)
- Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction (2020) (32)
- Statistical analysis plan for the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial (2014) (31)
- Polypill Strategy in Secondary Cardiovascular Prevention. (2022) (31)
- Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. (2016) (31)
- Parental and self-reported dietary and physical activity habits in pre-school children and their socio-economic determinants (2014) (30)
- Predictors of all‐cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry (2018) (30)
- Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. (2021) (30)
- Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. (2015) (30)
- Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. (2008) (30)
- More on subgroup analyses in clinical trials. (2008) (30)
- SAFETY AND EFFICACY OF EPLERENONE IN PATIENTS AT HIGH RISK FOR HYPERKALEMIA AND/OR WORSENING RENAL FUNCTION. ANALYSES OF THE EMPHASIS-HF STUDY SUBGROUPS (EPLERENONE IN MILD PATIENTS HOSPITALIZATION AND SURVIVAL STUDY IN HEART FAILURE) (2014) (30)
- The win ratio approach for composite endpoints: practical guidance based on previous experience. (2020) (30)
- Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation (2001) (29)
- Societal responsibilities of clinical trial sponsors (2001) (29)
- Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta‐analysis report (2013) (29)
- Safety of drug-eluting stents: demystifying network meta-analysis (2007) (29)
- Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: Results from the global DISCOVER study programme (2019) (29)
- The rise, fall, and possible resurrection of renal denervation (2016) (29)
- Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive (2012) (29)
- The contribution of drinking water lead to maternal blood lead concentrations. (1979) (28)
- The role of risk factors in heart attacks occurring in men with pre-existing ischaemic heart disease. (1988) (28)
- The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. (2005) (28)
- Combining Baseline Distal-to-Aortic Pressure Ratio and Fractional Flow Reserve in the Assessment of Coronary Stenosis Severity. (2015) (28)
- Comparison of intensive versus moderate chemotherapy of lymphocytic lymphomas. A progress report (1976) (28)
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. (2007) (28)
- Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. (2021) (28)
- How to interpret figures in reports of clinical trials (2008) (28)
- Eliciting and using expert opinions about influence of patient characteristics on treatment effects: a Bayesian analysis of the CHARM trials (2005) (28)
- In-Hospital Coronary Revascularization Rates and Post-Discharge Mortality Risk in Non-ST-Segment Elevation Acute Coronary Syndrome. (2019) (28)
- Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention (2016) (27)
- Environmental lead and children's intelligence: a review of recent epidemiological studies (1985) (27)
- Heart ‘omics’ in AGEing (HOMAGE): design, research objectives and characteristics of the common database (2014) (27)
- Mortality After Repeat Revascularization Following PCI or Coronary Artery Bypass Grafting for Left Main Disease: The EXCEL Trial. (2020) (27)
- Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction (2021) (27)
- Sample size requirements for prospective studies, with examples for coronary heart disease. (1989) (26)
- Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry (2019) (26)
- Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome (2018) (26)
- Absence of continuous three-shift workers. A comparison of traditional and rapidly rotating systems. (1972) (26)
- Response to letter regarding article, "effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial". (2014) (26)
- Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study. (2017) (26)
- Rationale, Design, and Baseline Characteristics of the EPICOR Asia Study (Long‐tErm follow‐uP of antithrombotic management patterns In Acute CORonary Syndrome patients in Asia) (2015) (26)
- Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. (2020) (25)
- The British Regional Heart Study: cardiovascular mortality and water quality. (1980) (25)
- The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. (1994) (25)
- Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. (2020) (25)
- MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT. (2019) (25)
- Large streamlined trials in cardiovascular disease. (2014) (25)
- Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments (2005) (24)
- VALIDATION OF A QUESTIONNAIRE TO MEASURE OVERALL MEDITERRANEAN LIFESTYLE HABITS FOR RESEARCH APPLICATION: THE MEDITERRANEAN LIFESTYLE INDEX (MEDLIFE). (2015) (24)
- Data monitoring in randomized controlled trials: surveys of recent practice and policies (2005) (24)
- Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study (2017) (24)
- Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician's Perspective. (2018) (24)
- Challenges in the Design and Interpretation of Noninferiority Trials: Insights From Recent Stent Trials. (2017) (23)
- Prediction of men at high risk of heart attack and its relevance to pilots. (1988) (23)
- Prognostic scores for detecting a high risk group: estimating the sensitivity when applied to new data. (1990) (23)
- Use of the Win Ratio in Cardiovascular Trials. (2020) (23)
- Analysis of How Emergency Physicians' Decisions to Hospitalize or Discharge Patients With Acute Heart Failure Match the Clinical Risk Categories of the MEESSI-AHF Scale. (2019) (23)
- A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry (2021) (23)
- Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials). (2012) (23)
- Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort study. (2021) (23)
- Ethnic differences in certified sickness absence. (1982) (23)
- Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme (2022) (23)
- Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. (2017) (23)
- White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry) (2017) (23)
- Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388) (2015) (22)
- A major trial needs three statisticians: why, how and who? (2004) (22)
- Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial (2014) (22)
- Current challenges for clinical trials of cardiovascular medical devices. (2014) (22)
- Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT (2020) (22)
- Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes (2011) (21)
- Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial (2021) (21)
- Calculation of Numbers-Needed-To-Treat in Parallel Group Trials Assessing Ordinal Outcomes: Case Examples from Acute Stroke and Stroke Prevention (2011) (21)
- Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) (2018) (21)
- Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials (2020) (21)
- Study design of a mortality trial with intravenous levosimendan - the SURVIVE study - in patients with acutely decompensated heart failure (2004) (20)
- Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. (2022) (20)
- Domiciliary thrombolysis by general practitioners. (1992) (20)
- Effectiveness and cost-effectiveness of a Yoga-based Cardiac Rehabilitation (Yoga-CaRe) program following acute myocardial infarction: Study rationale and design of a multi-center randomized controlled trial. (2019) (20)
- Infections Up to 76 Days After Stroke Increase Disability and Death (2017) (20)
- External Validation of the MEESSI Acute Heart Failure Risk Score (2019) (20)
- Issues in regulatory guidelines for data monitoring committees (2004) (19)
- Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial (2018) (19)
- Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial (2006) (19)
- Ambulance-delivered transdermal glyceryl trinitrate versus sham for ultra-acute stroke: Rationale, design and protocol for the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) trial (ISRCTN26986053) (2019) (19)
- When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches (2012) (19)
- Patients with acute heart failure discharged from the emergency department and classified as low risk by the MEESSI score (multiple risk estimate based on the Spanish emergency department scale): prevalence of adverse events and predictability. (2019) (19)
- Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial (2021) (19)
- Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction. (2015) (19)
- Effect of Barthel Index on the Risk of Thirty-Day Mortality in Patients With Acute Heart Failure Attending the Emergency Department: A Cohort Study of Nine Thousand Ninety-Eight Patients From the Epidemiology of Acute Heart Failure in Emergency Departments Registry. (2019) (19)
- Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? (2012) (18)
- Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial (2022) (18)
- Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. (2021) (18)
- Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study (2015) (18)
- Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction (2020) (18)
- Risk factors for ischaemic heart disease in British men. (1987) (18)
- Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT. (2019) (18)
- A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data (2020) (18)
- Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. (2021) (18)
- Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial (2021) (18)
- Headaches and migraine in colour retouchers (1970) (18)
- Effects of oral salbutamol and pirbuterol on FEV1, heart rate and blood pressure in asthmatics. (1976) (18)
- Statistical Appraisal of 6 Recent Clinical Trials in Cardiology: JACC State-of-the-Art Review. (2019) (18)
- Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial (2021) (17)
- Clinical Trials: A Pratical Approach. (1987) (17)
- INHANCE: An Adaptive Confirmatory Study with Dose Selection at Interim (2014) (17)
- Statistical Issues in Allowing for Noncompliance and Withdrawal (1993) (17)
- Improving public health by improving clinical trial guidelines and their application (2017) (17)
- Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry (2019) (17)
- Are risk minimization measures for approved drugs in Europe effective? A systematic review (2019) (17)
- The effect of internal thoracic artery grafts on long-term clinical outcomes after coronary bypass surgery. (2011) (17)
- Glycaemic control in patients with type 2 diabetes initiating second‐line therapy: Results from the global DISCOVER study programme (2019) (17)
- Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. (2017) (17)
- Assessment of quality indicators for acute myocardial infarction management in 28 countries and use of composite quality indicators for benchmarking (2020) (17)
- Life as an academic medical statistician and how to survive it. (1995) (17)
- The role of external evidence in data monitoring of a clinical trial. (1996) (16)
- New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment (2017) (16)
- Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS‐HF) (2015) (16)
- Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design (2020) (16)
- Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). (2018) (16)
- State of the art in comparative cancer clinical trials (1987) (16)
- Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents (2020) (16)
- ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data (2013) (16)
- Within-subject diastolic blood pressure variability: implications for risk assessment and screening. (1992) (16)
- Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease (2020) (16)
- Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. (2021) (16)
- Measuring the effect of a mobile coronary care unit upon the community. (1979) (16)
- Predictive value of repeated measurements of CD4 lymphocyte counts on progression to AIDS (1992) (16)
- Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids (2013) (16)
- Costs of an early intervention versus a conservative strategy in acute coronary syndrome. (2008) (16)
- Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement. (2022) (16)
- Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial (2021) (16)
- Interim Analyses in Randomized Clinical Trials (1986) (16)
- Challenges to Data Monitoring Committees When Regulatory Authorities Intervene. (2016) (15)
- Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. (2021) (15)
- Procedures of data and safety monitoring committees. (2001) (15)
- guidelines for reporting observational studies studies in epidemiology (STROBE) statement: Strengthening the reporting of observational (2007) (15)
- Surrogate endpoints in randomized cardiovascular clinical trials (2011) (15)
- Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial (2017) (15)
- Hormone replacement therapy and acute myocardial infarction: a large observational study exploring the influence of age. (2006) (15)
- Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial (2005) (15)
- Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
- Neural modulation for hypertension and heart failure. (2016) (14)
- British blood cholesterol values and the American consensus. (1985) (14)
- Statistical guidelines for contributors to medical journals (1983) (14)
- Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. (2021) (14)
- The science of risk models (2012) (14)
- Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention (2020) (14)
- Estimating the Lifetime Benefits of Treatments for Heart Failure (2020) (14)
- Clinical studies of 5-fluorouracil + premarin in the treatment of breast cancer. (1975) (14)
- Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS‐HF study (2016) (14)
- Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry (2016) (13)
- The pros and cons of non-inferiority (equivalence) trials (2002) (13)
- Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes (2022) (13)
- Relationship between sickness absence and meteorological factors. (1972) (13)
- Two-year outcomes of high bleeding risk patients with acute coronary syndrome after Biolimus A9 polymer-free drug-coated stents: a LEADERS FREE substudy. (2018) (13)
- Adjusting treatment comparisons to account for non‐randomized interventions: an example from an angina trial (2003) (13)
- Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial (2022) (13)
- Ethical Dilemmas and Malfunctions in Clinical Trials Research (2012) (13)
- Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure (2020) (13)
- Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled (2022) (13)
- Primary prevention trials in cardiovascular disease. (1990) (13)
- The prevalence, predictors and outcomes of guideline‐directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry (2018) (12)
- Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention: Insights From the PARIS Registry (2019) (12)
- Individualizing treatment choices using quantitative methods. (2014) (12)
- P002. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (2021) (12)
- Impact of Anemia and the Effect of Empagliflozin in HFrEF: findings from EMPEROR-Reduced. (2021) (12)
- Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience. (1977) (12)
- Predicting risk of cardiovascular events 1 to 3 years post‐myocardial infarction using a global registry (2019) (12)
- Characteristics and outcomes of medically managed patients with non-ST-segment elevation acute coronary syndromes: Insights from the multinational EPICOR Asia study. (2017) (12)
- Sex‐Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria (2021) (12)
- Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions (2022) (11)
- Quality management of a large randomized double-blind multi-centre trial: the ACTION experience. (2008) (11)
- Statistical analysis plan for the ‘Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage’ (TICH-2) trial (2017) (11)
- The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease (2021) (11)
- Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure (2021) (11)
- Rationale and design of the long‐Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post–myocardial infarction patients (TIGRIS) study (2017) (11)
- Predictors of high-cost hospitalization in the treatment of acute coronary syndrome in Asia: findings from EPICOR Asia (2018) (11)
- Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients (2015) (11)
- Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. (2019) (11)
- Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). (2017) (10)
- Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. (2017) (10)
- The Usefulness of the MEESSI Score for Risk Stratification of Patients With Acute Heart Failure at the Emergency Department. (2019) (10)
- MEESSI-AHF risk score performance to predict multiple post-index event and post-discharge short-term outcomes. (2020) (10)
- Shift and dayworkers' absence: relationship with some terms and conditions of service (1972) (10)
- ALCOHOL AND ISCHEMIC-HEART-DISEASE IN MIDDLE-AGED BRITISH MEN - REPLY (1987) (10)
- Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. (2013) (10)
- Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. (2019) (10)
- Association between anthropometry and high blood pressure in a representative sample of preschoolers in madrid. (2015) (10)
- Experience collecting interim data on mortality: an example from the RALES study (2001) (10)
- The Role of Statistics in Medical Research (1980) (10)
- Catch-up Growth in Cortisone–Treated Rats: Effects of Calcium and Vitamin D (1978) (10)
- Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (Arterial Revascularization Trial) (2018) (10)
- 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. (2020) (9)
- Effect of hospital volume on 90-day mortality after radical cystectomy for bladder cancer in Spain (2019) (9)
- Evaluation of antiarrhythmic drug efficacy in patients with an ICD. Unlimited potential or replete with complexity and problems? (1999) (9)
- POINT INVESTIGATORS. KETOROLAC, DICLOFENAC, AND KETOPROFEN ARE EQUALLY SAFE FOR PAIN RELIEF AFTER MAJOR SURGERY (2002) (9)
- Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: Findings from the EPICOR Asia study. (2020) (9)
- Post-war trends in sickness absence and unemployment in Great Britain. (1969) (9)
- Development of a Yoga-Based Cardiac Rehabilitation (Yoga-CaRe) Programme for Secondary Prevention of Myocardial Infarction (2019) (9)
- Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. (2016) (9)
- Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. (2018) (9)
- Antithrombotic management and long-term outcomes following percutaneous coronary intervention for acute coronary syndrome in Asia. (2020) (9)
- Relationship between sickness absence and length of service (1973) (8)
- Baseline characteristics of the 4011 patients recruited into the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial. (2014) (8)
- Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST) (2015) (8)
- Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. (2021) (8)
- HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, TRIGLYCERIDES, AND ISCHEMIC HEART-DISEASE - A REAPPRAISAL (1989) (8)
- Effects of long-term use of cardiovascular drugs (2015) (8)
- Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. (2022) (8)
- MEESSI-AHF risk score performance to predict multiple post-index event and post-discharge short-term outcomes. (2020) (8)
- Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study (2020) (8)
- Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction (2022) (8)
- Prediction of 1‐year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient‐level pooled analysis from three randomized trials (2016) (8)
- Daily Variations in Sickness Absence (1973) (8)
- A prospective, randomized trial of bivaliruclin in acute coronary syndromes: One year results from the ACUITY Trial (2007) (8)
- Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. (2021) (8)
- Individualizing treatment choices in the systolic blood pressure intervention trial (2018) (8)
- DETECTION AND IMPACT OF SUBCLINICAL CORONARY AND CAROTID ATHEROSCLEROSIS ON CARDIOVASCULAR RISK PREDICTION AND RECLASSIFICATION IN ASYMPTOMATIC US ADULTS: INSIGHTS FROM THE HIGH RISK PLAQUE BIOIMAGE STUDY (2014) (7)
- 45 – MEDICAL EQUIPMENT MAINTENANCE (1977) (7)
- Health-related quality of life 1–3 years post-myocardial infarction: its impact on prognosis (2021) (7)
- Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced (2022) (7)
- Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design. (2020) (7)
- Blood pressure and risk of dementia and its subtypes: a historical cohort study with long‐term follow‐up in 2.6 million people (2019) (7)
- Oseltamivir treatment for infl uenza in adults: a meta-analysis of randomised controlled trials (2015) (7)
- Cholesterol in elderly women (1992) (7)
- Prioritized Endpoints for Device-Based Hypertension Trials: the Win Ratio Methodology. (2020) (7)
- Design and rationale of the EMPEROR trials of, empagliflozin 10 mg once daily, in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved) (2019) (7)
- MRC trial of treating hypertension in older adults: Authors' reply (1992) (7)
- Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. (2019) (7)
- Effect of continuing versus stopping pre-stroke antihypertensive agents within 12 h on outcome after stroke: A subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial (2022) (6)
- The Historical Development of Clinical Trials (2013) (6)
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. (2020) (6)
- Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure (2004) (6)
- Lead Exposure and Children’s Intellectual Performance: the Institute of Child Health/Southampton Study (1989) (6)
- Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced (2022) (6)
- Central adjudication of serious adverse events did not affect trial’s safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial (2018) (6)
- Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk: A Cost Consequence Simulation From PARIS (2019) (6)
- Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). (2021) (6)
- The Justification for Randomized Controlled Trials (2013) (6)
- Prognostic Implications of N-terminal Pro-B Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. (2022) (6)
- CHARACTERISTICS AND OUTCOMES OF MEDICALLY MANAGED PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE MULTINATIONAL EPICOR ASIA STUDY (2015) (6)
- Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry (2016) (6)
- Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure (2022) (6)
- Association Between Clinical Pathways Leading to Medical Management and Prognosis in Patients With NSTEACS. (2017) (6)
- Predicting Subclinical Atherosclerosis in Low-RiskIndividuals (6)
- Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. (2016) (6)
- Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved’ [Eur J Heart Fail 2014;16:33–40] (2014) (5)
- Safety and Efficacy of Ticagrelor Monotherapy According to Drug-Eluting Stent Type: The TWILIGHT-STENT Study. (2021) (5)
- Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial (2022) (5)
- High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men (1986) (5)
- RAPID INTERVENTION WITH GLYCERYL TRINITRATE IN HYPERTENSIVE STROKE TRIAL-2 (RIGHT-2): SAFETY AND EFFICACY OF TRANSDERMAL GLYCERYL TRINITRATE, A NITRIC OXIDE DONOR (2016) (5)
- Statistical analysis plan for the ‘Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2)’ (2018) (5)
- The Nature of the P Value. (2016) (5)
- Long‐term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2‐year observations from the EPICOR Asia study (2020) (5)
- The Society for Clinical Trials supports United States legislation mandating trials registration (2004) (5)
- Raised blood pressure and risk of dementia. (2019) (5)
- Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate (2018) (5)
- Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention—Results from the PROMETHEUS registry (2020) (5)
- Analysis of repeated measures in clinical trials using summary statistics (1991) (5)
- Ever-Pregnant Female Blood Donors and Mortality Risk in Male Recipients. (2018) (5)
- Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced (2022) (5)
- Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial (2022) (5)
- Mediterranean dietary patterns in 3-5 year old children and their parents: the Program SI! study (2013) (4)
- Do patients necessarily have to start with an angiotension converting enzyme inhibitor in the treatment of heart failure? Results of the CARMEN (Carvedilol ACE Inhibitor Remodeling Mild CHF Evaluation) study (2003) (4)
- Evaluation of Antiarrhythmic Drug Efficacy in Patients with an ICD: (1999) (4)
- Authors' response to “Comment on adaptive increase in sample size when interim results are promising” (2011) (4)
- Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI (2022) (4)
- Detection and Estimation of J-Shaped Risk-Response Relationship (2008) (4)
- Socioeconomic Deprivation: An Important, Largely Unrecognized Risk Factor in Primary Prevention of Cardiovascular Disease (2022) (4)
- Introduction: The Rationale of Clinical Trials (2013) (4)
- Central masked adjudication of stroke diagnosis at trial entry offered no advantage over diagnosis by local clinicians: Secondary analysis and simulation (2018) (4)
- Optimal Sequential Screening Guidelines for Quantitative Risk Factors Measured with Error (1995) (4)
- Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study (2020) (4)
- 10 – Sickness Absence (1973) (4)
- Prolonged dual antiplatelet therapy in patients with non‐ST‐segment elevation myocardial infarction: 2‐year findings from EPICOR Asia (2020) (4)
- Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function (4)
- Baseline characteristics of the 3096 patients recruited into the ‘Triple Antiplatelets for Reducing Dependency after Ischemic Stroke’ trial (2017) (4)
- Nitrates and gastric cancer. (1985) (3)
- SUBCLINICAL ATHEROSCLEROSIS IN THE ABSENCE OF CARDIOVASCULAR RISK FACTORS: PRE-RISK STATUS IN THE PESA (PROGRESSION OF EARLY SUBCLINICAL ATHEROSCLEROSIS) STUDY (2017) (3)
- Sex differences in mortality after an acute coronary syndrome increase with lower country wealth and higher income inequality. (2021) (3)
- LEAD AND CHILDREN'S IQ (1987) (3)
- Comparative evaluation of combined radiation‐chlorambucil treatment of ovarian carcinomatosis (1975) (3)
- Phase I-II trial of intramuscularly administered bleomycin. (1977) (3)
- Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced (2022) (3)
- Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme (2020) (3)
- Correction to: Rationale and design of two randomized sham‑controlled of catheter‑based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN‑OFF MED Pivotal) and presence (SPYRAL HTN‑ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian (2020) (3)
- BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS (2014) (3)
- Monday, 27 August 2012 (2012) (3)
- Oseltamivir for influenza – Authors' reply (2015) (3)
- Natural history of breast cancer. (1965) (3)
- IMPACT OF EJECTION FRACTION ON MORTALITY IN PATIENTS UNDERGOING PCI: A PATIENT-LEVEL POOLED ANALYSIS FROM THE REPLACE-2, ACUITY AND HORIZONS-AMI TRIALS (2012) (3)
- Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled. (2022) (3)
- Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial (2022) (3)
- Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry (2019) (3)
- Predicting risk of death from cardiovascular disease - Reply (2001) (3)
- ROUTINE INVASIVE VERSUS SELECTIVE INVASIVE STRATEGY AND LONG-TERM OUTCOMES IN PATIENTS WITH REDUCED RENAL FUNCTION PRESENTING WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME (2012) (3)
- Drug-Coated Stents Versus Bare-Metal Stents in Academic Research Consortium-Defined High Bleeding Risk Patients. (2020) (3)
- Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry (2019) (3)
- Methods of Randomization (2013) (3)
- Lateresults oftheRoyal FreeHospital prospective controlled trial ofprednisolone therapy inhepatitis Bsurface antigen negative chronic active hepatitis (1980) (3)
- Reporting noninferiority trials--reply. (2013) (3)
- Cardiovascular risk factors in middle-aged men in 24 towns (1981) (3)
- The Clinical outcomes, healthcare resource utilization, and related costs (COHERENT) model. Application in heart failure patients. (2021) (2)
- A NOVEL APPROACH TO QUANTIFYING RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS 1-3 YEARS POSTMYOCARDIAL INFARCTION: INSIGHTS FROM THE GLOBAL PROSPECTIVE TIGRIS REGISTRY (2019) (2)
- Accounting For Non-Independent Observations In 2×2 Tables, With Application To Correcting For Family Clustering In Exposure-Risk Relationship Studies (2002) (2)
- Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction (2021) (2)
- NEONATAL HYPERBILIRUBINAEMIA, OXYTOCIN, AND SEX OF INFANT (1982) (2)
- Prognosis ofpatients with acutemyocardial infarction admitted toa coronarycareunit ii:Survival afterhospital discharge (1977) (2)
- Comments on Adaptive increase in sample size when interim results are promising: A practical guide with examples' by C.R. Mehta and S.J. Pocock reply (2012) (2)
- Relationship between late loss, diameter stenosis and target lesion revascularization after stent implantation: An examination of surrogate endpoints from a pooled analysis of eight large randomized DES trials (2006) (2)
- Associations between change in blood pressure and functional outcome, early events and death: results from the Efficacy of Nitric Oxide in Stroke trial (2019) (2)
- Use of prasugrel and clinical outcomes in African‐American patients treated with percutaneous coronary intervention for acute coronary syndromes (2019) (2)
- Phase II trial with bleomycin, CCNU, and streptozotocin in patients with metastatic cancer of the breast. (1977) (2)
- Further Aspects of Data Analysis (2013) (2)
- Bayesian Approaches to Randomized Trails - Discusion (1994) (2)
- Risks to healthcareworkers following tracheal intubation of patientswith COVID-19: a prospective international multicentre cohort study (2020) (2)
- Insulin glargine and cancer – Authors' reply (2009) (2)
- TCT-835 Validation of PARIS Risk Scores in Patients Treated With Everolimus-Eluting Stents for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial (2018) (2)
- A win ratio approach to comparing ordinal or non-normal outcomes in clinical trials (2013) (2)
- Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study. (2020) (2)
- Comparative evaluation of combined radiation-chlorambucil treatment of ovarian carcinomatosis. (1976) (2)
- 420-P: Micro- and Macrovascular Events in Patients with T2D—Results from the Global DISCOVER Study (2019) (2)
- Does midlife obesity really lower dementia risk? - Authors' reply. (2015) (2)
- Feasibility and Exploratory Efficacy Evaluation of the Embrella Embolic Deflector System for the Prevention ofCerebral Emboli in Patients Undergoing Transcatheter Aortic ValveReplacement (2)
- Tocilizumab and mortality in hospitalised patients with covid-19. A systematic review comparing randomised trials with observational studies (2021) (2)
- Cost of coronary angioplasty versus coronary artery bypass surgery (1994) (2)
- Glycaemic, lipid and blood pressure control according to guidelines in patients initiating second-line glucose-lowering therapy: results from the global DISCOVER study (2017) (2)
- Anticoagulation Strategies in Non-Critically Ill Patients Hospitalized with COVID-19: A Randomized Clinical Trial (2023) (2)
- EST 0469B--comparison of high- and low-dose cyclophosphamide in human lung cancer. (1978) (2)
- TWO-YEAR OUTCOMES POST-DISCHARGE IN ASIAN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS): FINDINGS FROM THE EPICOR ASIA STUDY (2015) (2)
- WHITE BLOOD CELL COUNT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION IN THE CONTEMPORARY ERA: INSIGHTS FROM THE PARIS STUDY (2017) (2)
- Basic Principles of Statistical Analysis (2013) (2)
- Blood pressure reduction and anti‐hypertensive treatment choice: A post‐hoc analysis of the SPRINT trial (2021) (2)
- Blinding and Placebos (2013) (2)
- TCT-111 Relationship between anemia, prasugrel use and clinical outcomes in contemporary percutaneous coronary intervention for acute coronary syndromes. (2016) (2)
- Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial (2021) (2)
- 517 Contemporary surgical outcomes of radical cystectomy in a decentralized health system. Does volume matter (2016) (2)
- Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutancous coronary intervention: One year results from the randomized ACUITY trial (2007) (2)
- Can we improve the statistical analysis of vascular prevention trials? Assessment of ordinal outcomes (2007) (2)
- Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial. (2022) (2)
- Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study. (2019) (2)
- 28 – THE IMPLEMENTATION OF A MEDICAL ENGINEERING SERVICE (1977) (2)
- Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial (2022) (2)
- Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department (2018) (2)
- Systematic Reviews (1995) (2)
- Relationship between nitrate headache and outcome in patients with acute stroke: results from the efficacy of nitric oxide in stroke (ENOS) trial (2020) (1)
- Clinical Impact of Influenza Vaccination after ST- and Non-ST-segment elevation Myocardial Infarction Insights from the IAMI trial. (2022) (1)
- Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumab (2021) (1)
- 1279-P: Socioeconomic Factors Associated with Poor Glycemic Control in People with Type 2 Diabetes: The DISCOVER Study (2019) (1)
- Clinical benefits of Eplerenone in patients with systolic NYHA II heart failure when initiated shortly after hospital discharge (2013) (1)
- BRITISH REGIONAL HEART-STUDY - AN ECG ASSESSMENT OF RISK (1988) (1)
- Abstract 15409: Differences in 1-Year Mortality Risk Between Survivors of ST-Segment Elevation and Non ST-Segment Elevation ACS: Insights From the EPICOR Study (2013) (1)
- P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease (2019) (1)
- Cracking the NNT Code: Effect of Ivabradine on Recurrent Hospitalizations (2015) (1)
- 7 Systolic and Diastolic Blood Pressures in the Prediction of Heart Attacks and Stroke (1987) (1)
- TCT-271 Sex-related differences in outcomes after percutaneous coronary intervention (PCI) in patients with diabetes presenting with acute coronary syndrome (ACS): Results from the PROMETHEUS study. (2016) (1)
- Abstract 16705: EPICOR: An International Study of the Duration of Dual Antiplatelet Therapy in Survivors of Acute Coronary Syndromes (2014) (1)
- SYSTOLIC AND DIASTOLIC BLOOD PRESSURES IN PREDICTION OF HEART-ATTACKS AND STROKE (1988) (1)
- Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes (2021) (1)
- Changes in HbA(1c) and weight after initiation of second-line therapy in patients with type 2 diabetes in clinical practice (2017) (1)
- USE OF POTENT P2Y12 INHIBITORS IN AFRICAN-AMERICAN PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES (2017) (1)
- Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia (2021) (1)
- Diabetes association with self‐reported health, resource utilization, and prognosis post‐myocardial infarction (2020) (1)
- Authors' reply (2016) (1)
- Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). (2010) (1)
- Alcohol and ischaemic heart disease in middle aged British men: (1987) (1)
- Response: Response to the Stampfer commentary (2006) (1)
- TCT CONNECT-417 Impact of Renal Denervation on Plasma Renin Activity and Relationship of Baseline Plasma Renin Activity to Blood Pressure Lowering Response to Renal Denervation in the SPYRAL HTN-OFF MED Pivotal trial (2020) (1)
- A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions (2021) (1)
- The Use of Figures in Epidemiological Publications: A Survey of Current Practice and Consequent Recommendations (2012) (1)
- 5261Linear ongoing risk of major cardiovascular events in a global prospective registry of high-risk patients with stable coronary disease: insights from the TIGRIS study (2018) (1)
- TREATMENT OF LEFT MAIN CORONARY ARTERY DISEASE IN PATIENTS WITH DIABETES: 3-YEAR OUTCOMES COMPARING CABG AND PCI WITH EVEROLIMUS-ELUTING STENTS FROM THE EXCEL STUDY (2017) (1)
- Characteristics and survival of heart failure patients in whom left ventricular ejection fraction is not assessed: analysis from a large-scale individual patient meta-analysis (MAGGIC) (2010) (1)
- Reed Elsevier and the arms trade revisited (2007) (1)
- 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome (2020) (1)
- Discussion of paper by C. B. Begg (1990) (1)
- PREDICTORS OF ISCHEMIC EVENTS WITHIN AND AFTER 1 YEAR AFTER AN ACUTE CORONARY SYNDROME: RESULTS FROM THE EPICOR REGISTRY (2017) (1)
- Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis (2007) (1)
- Discussion: M K B Parmar and David Machin, monitoring clinical trials; Experience of, and proposals under consideration by the Cancer Therapy Committee of the British Medical Research Council (1993) (1)
- Abstract 109: Changes in Plasma Renin Activity After Renal Denervation in the Spyral Htn-Off Med Trial (2019) (1)
- Industrial injuries. (1972) (1)
- 1200Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3 (2019) (1)
- TCT-215 Predictors of 1-year mortality at hospital discharge after ACS STEMI and NSTE-ACS: a new risk score from the EPICOR study (2013) (1)
- Chronic kidney disease is associated with increased mortality, bleeding, and ischemic events in moderate and high-risk patients with acute coronary syndromes: An ACUITY substudy (2007) (1)
- PATTERNS OF ADHERENCE TO DUAL ANTIPLATELET THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING COMPLEX PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE PARIS REGISTRY (2015) (1)
- Hospitalizations and Mortality in Patients With Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial. (2022) (1)
- OPL091 Continuing prior antihypertensive medication in acute stroke lowers blood pressure: Data from the continue vs stop arm of the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial (2005) (1)
- Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved (2022) (1)
- Predicting risk of death from cardiovascular disease (2001) (1)
- Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials (2021) (1)
- Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction. (2022) (1)
- Health Status Assessed With Eq-5d In People With Type 2 Diabets Participating In the Leader Trial (2018) (1)
- Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. (2022) (1)
- In Discussion of “Analysing Geographic Variations in Cardiovascular Mortality: Methods and Results” (1982) (1)
- Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. (2022) (1)
- RELATIONSHIPS BETWEEN ANTITHROMBOTIC MANAGEMENT PATTERNS AND IN-HOSPITAL OUTCOMES IN ACUTE CORONARY SYNDROME: AN INTERNATIONAL PERSPECTIVE FROM THE EPICOR ASIA STUDY (2016) (1)
- Covariate Adjustment in Cardiovascular Randomized Controlled Trials: Its Value, Current Practice, and Need for Improvement. (2022) (1)
- Multimorbidity, functional impairment, and mortality in older patients stable after prior acute myocardial infarction: Insights from the TIGRIS registry (2022) (1)
- Abstract 14959: Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial (2020) (1)
- Re: "quality of reporting of observational longitudinal research". (2005) (1)
- Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial (2021) (1)
- 291 Ticagrelor monotherapy after percutaneous coronary intervention in high-risk patients with prior myocardial infarction: a prespecified twilight substudy (2021) (1)
- Subgroup analyses in randomized clinical trials: Value and limitations Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. (2021) (1)
- Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. (2022) (1)
- Statistical Controversies in Reporting of Clinical Trials (2017) (1)
- Weight loss (but not weight gain) is a strong predictor of mortality in chronic heart failure: Findings from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program (2005) (1)
- Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry (2021) (1)
- TCT-52 Bivalirudin reduces cardiac mortality in patients with and without major bleeding: The HORIZONS-AMI trial (2012) (1)
- Lowering systolic blood pressure to 120 mmHg or The Lancet's true grit. (2021) (1)
- IMPACT OF RENAL DENERVATION ON PLASMA RENIN ACTIVITY AND RELATIONSHIP OF BASELINE PLASMA RENIN ACTIVITY TO BLOOD PRESSURE LOWERING RESPONSE TO RENAL DENERVATION IN THE SPYRAL HTN-OFF MED PIVOTAL TRIAL (2020) (0)
- Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause (2022) (0)
- TCT-105 Prevalence of prasugrel use and associations between type of acute coronary syndrome and 1-year clinical outcomes. (2016) (0)
- Body Mass Index and Prognosis in Patients With Chronic Heart Failure Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program Heart Failure (2007) (0)
- TCT-487 Temporal Associations Between Myocardial Infarction, Major Bleeding and Mortality Risk in ACS Patients Undergoing PCI: Insights from the PROMETHEUS Cohort (2015) (0)
- Individual cardiovascular risk cannot be predicted. Authors' reply (2001) (0)
- Body mass index and risk of dementia in two million people over two decades (2015) (0)
- Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19 (2023) (0)
- Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. (2023) (0)
- EFFECT OF RENAL DENERVATION IN ATTENUATING THE MORNING SURGE IN BLOOD PRESSURE (2019) (0)
- Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction – EMPEROR-Preserved trial (2022) (0)
- TCT-608 Implementation of Bayesian Study Design in the SPYRAL HTN-OFF MED Pivotal Trial (2019) (0)
- Lead and children's IQ. (1987) (0)
- OUTCOMES OF CONTEMPORARY NON-INFERIORITY VERSUS SUPERIORITY CARDIOVASCULAR TRIALS (2021) (0)
- TCT-33 Mortality After Repeat Revascularization Following PCI or CABG for Left Main Coronary Artery Disease: The EXCEL Trial (2018) (0)
- Variation in the incidence of diverticular within the city of Edinburgh disease (2006) (0)
- Relative Prognostic Utility of Different Bleeding Scales Among Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction: The HORIZONS-AMI Trial (2008) (0)
- Forms and Data Management (2013) (0)
- 1448-P: Potential Overtreatment of Older Patients with T2D: The Global DISCOVER Study (2019) (0)
- Abstract 4509: Individual Patient Risks of Major Bleeding and Myocardial Infarction and Their Implications for Mortality and for Treatment Choice in Acute Coronary Syndromes: Findings From the ACUITY Trial (2009) (0)
- MULTI-MORBIDITY, FUNCTIONAL IMPAIRMENT AND MORTALITY IN OLDER PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION: A REPORT FROM THE TIGRIS REGISTRY (2020) (0)
- TICAGRELOR MONOTHERAPY AFTER PCI ACROSS THE SPECTRUM OF HIGH-RISK PATIENTS: A DEEP DIVE INTO THE TWILIGHT TRIAL (2022) (0)
- The statistical consultant in action: Consultancy in a medical school, illustrated by a clinical trial for treatment of primary biliary cirrhosis (1987) (0)
- Natural history of breast cancer. (1982) (0)
- TCT-221 Predictors of optimal medical therapy on discharge after percutaneous coronary intervention for acute coronary syndrome: An analysis of the PROMETHEUS registry. (2016) (0)
- Abstract P154: Win Ratio Methodology Demonstrates Consistency Of Benefit Across Different Blood Pressure Reduction Thresholds Following Renal Denervation In The Spyral Htn-on Med Pilot Study (2021) (0)
- IMPACT OF A SWITCH FROM DUAL ANTIPLATELET THERAPY TO SINGLE ANTIPLATELET THERAPY IN DIABETES AND NON-DIABETES POST ACS: INSIGHTS FROM THE EPICOR AND EPICOR-ASIA STUDIES (2017) (0)
- Bradford Hill Lectures (2005) (0)
- P1760Incidence and effects of stroke, MI and bleeding on mortality among patients with ACS undergoing PCI: a comparative analysis from the PROMETHEUS registry (2019) (0)
- Abstract 15408: Long-term Antithrombotic Management Patterns After Acute Coronary Syndromes: 2-[[Unsupported Character - Codename ]]years Follow-up in the EPICOR Asia Study (2015) (0)
- CENTRAL ILLUSTRATION Long-Term Use of Cardiovascular Drugs : Challenges for Research and for Patient Care CONCERNS WITH CURRENT LONG-TERM USE OF CARDIOVASCULAR DISEASE DRUGS Unclear guidelines for drug use after myocardial infarction (0)
- Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs. (2022) (0)
- Translating statistical findings into plain English – Authors' reply (2009) (0)
- Conservative, True Selective Invasive, and Routine Invasive Strategies in Non-ST-Segment Elevation Acute Coronary Syndromes Reply (2010) (0)
- Abstract 16711: Timing of Angiography in Non-ST-elevation Acute Coronary Syndromes and the Effect on Cardiovascular Mortality and Myocardial Infarction. (2010) (0)
- Body mass index and risk of future dementia over two decades in two million people (2014) (0)
- 0484: The LEADERS FREE Trial: a double blind randomized comparison of a BMS and a polymer-free Drug Coated Stent (DCS) in 2,466 patients at high bleeding risk and treated with one month DAPT only (2016) (0)
- Systolic blood pressure independent treatment effect on the risk of stroke and coronary artery disease: An individual patient data meta-analysis of hypertension trials (2004) (0)
- 1 Blood Lead, Blood Pressure and Renal Function (1984) (0)
- Coronary Artery Disease ealth-Related Quality of Life After nterventional or Conservative Strategy n Patients With Unstable Angina or on – ST-Segment Elevation Myocardial Infarction ne-Year Results of the Third Randomized ntervention Trial of Unstable Angina ( RITA-3 ) (2016) (0)
- TCT-225 Impact of Age on the Disruption of Dual Antiplatelet Therapy: Analysis from the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented) Patients Registry (2015) (0)
- Abstract WP76: Baseline Characteristics of the 3,096 Patients Recruited Into the ‘Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke’ (TARDIS) Trial (2017) (0)
- LONG-TERM CARDIOVASCULAR OUTCOMES IN A REAL-LIFE COHORT OF CONTEMPORARY MYOCARDIAL INFARCTION PATIENTS FREE OF EVENTS AT 1 YEAR: A SUBANALYSIS OF THE EPICOR STUDY (2015) (0)
- OralBleeding and the Hazards of AnticoagulationTCT-89 Tradeoff between Myocardial Infarction and Bleeding in Relation to Bleeding Risk: insights from PARIS registry (2017) (0)
- TCT-313 Incidence and Impact of Major Bleeding Events After PCI or CABG for Left Main Coronary Artery Disease: The EXCEL Trial (2019) (0)
- Sequential Methods in the Design and Analysis of Clinical Trials (2010) (0)
- P1932Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study (2019) (0)
- disease . pre-existing ischaemic heart attacks occurring in men with The role of risk factors in heart (2005) (0)
- CHANGES IN VISIT-TO-VISIT BP VARIABILITY WITH BETABLOCKER, DIURETIC AND CALCIUM ANTAGONIST: 6C.09 (2011) (0)
- EVALUATION OF THE ACADEMIC RESEARCH CONSORTIUM HIGH BLEEDING RISK DEFINITION IN PATIENTS TREATED WITH DRUG-COATED STENTS AND BARE-METAL STENTS FROM THE LEADERS FREE I & II TRIALS (2020) (0)
- Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled (2022) (0)
- Abstract MP38: The Program SI! Intervention for Enhancing a Healthy Lifestyle among Children aged 3 to 5: A Cluster Randomized Trial (2014) (0)
- Blood Cholesterol and Risk of Dementia in a Retrospective Cohort of Over 1.8 Million People Over Two Decades (2021) (0)
- P511Incidence and patterns of dual antiplatelet therapy cessation among patients with peripheral arterial disease after percutaneous coronary intervention: insights the PARIS registry (2017) (0)
- TCT-55 Risk-Benefit Analysis of Upstream Antithrombotic Therapy in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes Prior to Coronary Angiography. (2016) (0)
- Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot ’Prevention of Decline in Cognition after Stroke Trial’ (POD- (2018) (0)
- Occlusal Adjustment vs Placebo for Chronic Temporomandibular Disorders. The MAP Randomized Clinical Trial (2020) (0)
- Estimating effects of change in individual risk factors in a multifactorial intervention trial with group randomization (1991) (0)
- Open letter to the Heads of the European Regulatory Agencies (2008) (0)
- USE OF CLOPIDOGREL VERSUS PRASUGREL IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: FACTORS INFLUENCING REAL-WORLD THERAPEUTIC DECISION-MAKING (2016) (0)
- Impact of Major Adverse Cardiac Events and Major Bleeding on Overall Mortality in Patients with Acute Myocardial Infarction: Results from the HORIZONS-AMI Trial (2008) (0)
- Statistical Essentials in the Design and Analysis of Clinical Trials (2011) (0)
- Abstract 3169: Increase in Risk of Death in Early Months Following Hospitalization for Heart Failure: Observations from the CHARM Program (2006) (0)
- S40 Estimation of rate of change in longitudinal studies with attrition with application in hiv clinical trials (1997) (0)
- IMPACT OF MAJOR BLEEDING AFTER CARDIAC SURGERY ON SUBSEQUENT MORTALITY: THE ACUITY TRIAL (2011) (0)
- RELATIONSHIP BETWEENSICKNESSABSENCEAND METEOROLOGICALFACTORS (1972) (0)
- Variation intheincidence ofdiverticular within thecity ofEdinburgh disease (2017) (0)
- TCT-66 Effects of dual antiplatelet therapy cessation among patients with diabetes mellitus after PCI with DES. (2016) (0)
- Problems in the reporting of trials and (mis)interpretation of results: Lessons from the RITA-3 trial (2003) (0)
- 640 Total bilirubin and red cell distribution width are powerful independent predictors of outcome in chronic heart failure: results from the CHARM program (2005) (0)
- ANTITHROMBOTIC MANAGEMENT PATTERNS AND LONG-TERM OUTCOMES OF PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN ASIA: AN EPICOR ASIA (LONG-TERM FOLLOW-UP OF ANTITHROMBOTIC MANAGEMENT PATTERNS IN ACUTE CORONARY SYNDROME PATIENTS IN ASIA) ANALYSIS (2018) (0)
- Risk stratification in clinical trials: a subgroup to be encouraged (2013) (0)
- The impact of stopping rules on meta-analyses (1990) (0)
- Clinical Trials: A Statistician's Perspective1 (1999) (0)
- 1628-P: Changes in HbA1c and Treatment in the Second Year following Initiation of Second-Line Therapy in People with T2D—The Global DISCOVER Study (2019) (0)
- TCT-300 Combining baseline distal-to-aortic pressure ratio and fractional flow reserve in the assessment of coronary stenosis severity (2015) (0)
- The quality, content and style of epidemiological publications: A survey of recent practice (2003) (0)
- ASSOCIATIONS BETWEEN DIFFERENT MODES OF DAPT CESSATION AND MAJOR ADVERSE EVENTS AT 6 MONTHS AND BEYOND: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
- Acute Coronary Syndrome Long-Term Benefit of Early Pre-Reperfusion Metoprolol Administration in Patients With Acute Myocardial Infarction Results From the METOCARD-CNIC Trial ( Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction ) (2014) (0)
- Reply: Do the 10-Year Mortality Outcomes of RITA-3 Inform Contemporary Clinical Practice? (2016) (0)
- Percutaneous coronary intervention for stable angina in ORBITA (2018) (0)
- HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL, ALCOHOL INTAKE AND ISCHEMIC HEART-DISEASE (1985) (0)
- Abstract 261: Global Patterns of Comprehensive Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes Mellitus Insights From the Global DISCOVER Registry (2018) (0)
- TCT-747 Associations between Stent Diameter and Clinical Outcomes in ACS PCI Using Second Generation Drug-Eluting Stents: From the PROMETHEUS Study (2017) (0)
- INCIDENCE, PREDICTORS AND IMPACT OF STROKE AFTER PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES: RESULTS FROM THE PROMETHEUS REGISTRY (2016) (0)
- ASSOCIATIONS BETWEEN DUAL ANTIPLATELET THERAPY CESSATION AND MACE DUE TO STOPPING ONE OR BOTH DRUGS: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
- BLOOD-LEAD IN MENTALLY RETARDED CHILDREN (1977) (0)
- Twelve-Month Changes in HbA1c, Fasting Plasma Glucose, and Weight among Patients with Type 2 Diabetes in 37 Countries—DISCOVER (2018) (0)
- The Win Ratio Method in Heart Failure Trials: Lessons Learnt From Empulse. (2023) (0)
- Can we trust claims from clinical trial reports? A statistician's perspective (2019) (0)
- Long-term outcomes of patients with acute coronary syndromes and chronic renal insufficiency undergoing percutaneous coronary intervention and being treated with bivalirudin vs heparin plus a glycoprotein IIb/IIIa inhibitor: Results from the randomized ACUITY Trial (2007) (0)
- O116 Does aspirin interfere with the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in systolic chronic heart failure?: Analysis of the EMPHASIS-HF study (2014) (0)
- Prasugrel or clopidogrel in patients with acute coronary syndromes at high thrombotic risk: results from the PROMETHEUS study (2021) (0)
- Shift anddayworkers' absence: relationship withsome termsandconditions ofservice (1972) (0)
- INCIDENCE, PATTERNS AND ASSOCIATIONS BETWEEN DUAL ANTIPLATELET THERAPY CESSATION AND RISK FOR ADVERSE EVENTS IN HIGH-RISK PATIENTS: INSIGHTS FROM THE PARIS REGISTRY (2018) (0)
- REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups (2020) (0)
- TCT-844 Very Late (>1 Year) Stent-Related Adverse Cardiovascular Events: Individual Patient Data and Network Meta-Analyses From 19 Randomized Clinical Trials (2019) (0)
- The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. (2020) (0)
- Individualized HbA1c Targets in People with Type 2 Diabetes Initiating Second-Line Therapy—The Global DISCOVER Study (2018) (0)
- Temporal Trends in the Use of Sodium-Glucose Cotransporter 2 Inhibitors—The Global DISCOVER Study (2018) (0)
- OUTCOMES OF PCI VERSUS CABG IN LEFT MAIN DISEASE ACCORDING TO SYNTAX SCORE BY SITE VERSUS ANGIOGRAPHIC CORE LABORATORY ASSESSMENT: INSIGHTS FROM THE EXCEL TRIAL (2017) (0)
- Reply: Last Nail in the Coffin for Propensity Scores in Observational Cardiovascular Studies? (2017) (0)
- Predictors of 2-year mortality following hospital discharge in patients with acute coronary syndromes: a new risk score from the EPICOR and EPICOR Asia studies (2016) (0)
- TCT-219 Influence Of Anemia On Physician-Recommended DAPT Discontinuation After Percutaneous Coronary Intervention. (2016) (0)
- 33A Assessment of the variation of treatment effect over time: An example in hypertension treatment (1994) (0)
- Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". (2019) (0)
- USE OF EVIDENCE-BASED PREVENTIVE MEDICAL THERAPIES 1-3 YEARS POST-MYOCARDIAL INFARCTION IN THE PROSPECTIVE GLOBAL TIGRIS REGISTRY (2019) (0)
- CARING FOR THE CRITICALLY ILL PATIENT Dexmedetomidine vs Midazolam or Propofol for SedationDuringProlongedMechanicalVentilation Two Randomized Controlled Trials (2012) (0)
- The impact of underlying risk and gender on the benefit of early intervention in non-ST elevation acute coronary syndrome patients: findings from the RITA-3 trial (2005) (0)
- Body Mass Index and Risk of Dementia in a Cohort Study of Two Million People in UK Primary Care Database: 650. (2015) (0)
- Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial (2022) (0)
- studies: a survey of recent practice Issues in the reporting of epidemiological (2004) (0)
- Statistical controversies in meta-analysis: Fixed effects or random effects models? (1991) (0)
- Implications of Biomarker Discordance After Coronary Artery Revascularization: The EXCEL Trial. (2021) (0)
- A practical, validated model for prediction of risk in chronic heart failure (2006) (0)
- TCT-211 Incidence and Impact of Dual Antiplatelet Therapy Cessation on Clinical Outcomes in Patients with Renal Dysfunction: Insights from the PARIS Registry. (2016) (0)
- Comparison of catheterization lab initiated abciximab and double-bolus eptifibatide during percutaneous coronary intervention in acute coronary syndromes: an ACUITY substudy (2007) (0)
- STABLE CORONARY DISEASE IN HIGH VASCULAR RISK PATIENTS AND QUALITY OF LIFE: INSIGHTS FROM THE LONG TERM RISK, CLINICAL MANAGEMENT AND HEALTHCARE RESOURCE UTILIZATION OF STABLE CORONARY ARTERY DISEASE (TIGRIS) REGISTRY (2016) (0)
- RISK-FACTORS IN PREDICTION OF HEART-ATTACKS IN MEN WITH PRE-EXISTING ISCHEMIC HEART-DISEASE (1988) (0)
- Reply: Survival Differences in Clinical Trials With Long-Term Follow-up. (2016) (0)
- TEMPORAL ASSOCIATIONS BETWEEN TIME AFTER PERCUTANEOUS CORONARY INTERVENTION, DUAL ANTIPLATELET THERAPY CESSATION AND STENT THROMBOSIS IN THE CONTEMPORARY PCI ERA: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
- Clinical Trials (1982) (0)
- GW29-e1127 Differences in two-year outcomes for patients with non‒ST-segment elevation myocardial infarction or unstable angina treated with medication only - findings from the EPICOR Asia study (2018) (0)
- Impact of Blood Transfusion and Other Bleeding Measures on Subsequent Mortality Among Patients Undergoing Primary PCI for Acute Myocardial Infarction: The HORIZONS-AMI Trial (2008) (0)
- Organization and Planning (2013) (0)
- Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: insights from a large PCI registry. (2023) (0)
- PODCAST Trial Investigators; (2017) Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot ’Prevention of Decline in Cognition (2019) (0)
- Outcomes of bivalirudin in moderate and high risk patients with acute coronary syndromes and renal insufficiency: An ACUITY substudy (2007) (0)
- P5471Baseline characteristics, healthcare resource use and clinical outcomes of stable post-myocardial infarction patients with diabetes: insights from the global prospective TIGRIS study (2019) (0)
- Improved behavior in children aged 3 to 5 after one year of a school-based intervention for healthy living (2013) (0)
- Treatment and long-term results of acute coronary syndrome (ACS) in patients on chronic oral anticoagulants (OAC): data from the EPICOR (NCT01171404) study (2015) (0)
- TCT-110 Incidence, predictors, and outcomes of DAPT disruption due to non-compliance versus bleeding after PCI: insights from the PARIS Registry (2018) (0)
- IMPACT OF AGE ON THE MODES OF DUAL ANTIPLATELET THERAPY CESSATION: ANALYSIS FROM THE PARIS (PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS) REGISTRY (2015) (0)
- TCT-206 Tailoring the Intensity of Antiplatelet Pharmacotherapy to Ischemic and Bleeding Risk: A Cost Optimizing Simulation From PARIS. (2016) (0)
- TCT-307 Vascular Closure Device Use After PCI for Left Main Disease: Analysis From the EXCEL Trial (2019) (0)
- Moderated PosterAdjunct Pharmacology after PCI: DAPTTCT-545 Individualizing DAPT Duration after Coronary Stenting for Patients at High Bleeding Risk – The LEADERS FREE trade-off score (2017) (0)
- On the design and analysis of randomized clinical trials with multiple end-points (1991) (0)
- Duration of Dual Antiplatelet Therapy AfterDrug-Eluting Stent Implantation (0)
- COMMUTER TRAVELAND SICKNESSABSENCEOF LONDON OFFICEWORKERS (1972) (0)
- Impact of different antiplatelet therapy cessation modes on outcomes in patients treated with ticagrelor with or without aspirin after PCI: the twilight-antiplatelet cessation study (2022) (0)
- Author ' s response to reviews Title : The Program SI ! intervention for enhancing a healthy lifestyle in preschoolers : First results from a cluster randomized trial (2013) (0)
- Geographical analysis of cardiovascular mortality: a cautionary note (1980) (0)
- Author ' s response to reviews Title : The Program SI ! intervention for enhancing a healthy lifestyle in preschoolers : First results from a cluster randomized trial (2013) (0)
- PHP38 USE OF PATIENT-REPORTED OUTCOMES IN EVALUATION OF HEART FAILURE DEVICE THERAPY: THE REGULATORY PERSPECTIVE (2004) (0)
- Olivier, A. et al. (2017) Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: insight from the EMPHASIS-HF trial. European Journal of Heart (2018) (0)
- TCT CONNECT-64 Impact of DAPT Cessation in High Bleeding-Risk Patients Undergoing PCI: Insights From the PARIS Registry (2020) (0)
- TCT-746 Outcomes by Total Stent Length in ACS PCI with Second Generation Drug-Eluting Stents: Results from the PROMETHEUS Study (2017) (0)
- TICAGRELOR MONOTHERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN HIGH-RISK PATIENTS WITH OR WITHOUT HISTORY OF MYOCARDIAL INFARCTION. A PRESPECIFIED TWILIGHT SUBSTUDY (2021) (0)
- Abstract 18342: Post Discharge and Early Clinical Benefits of Eplerenone in Patients With Systolic Nyha Ii Heart Failure: Insight From Emphasis-hf (2013) (0)
- Publication and Interpretation of Findings (2013) (0)
- Vascular Events in Patients with Type 2 Diabetes in the Year following Initiation of Second-Line Therapy-The DISCOVER Study (2018) (0)
- Therole ofrisk factors inheart attacks occurring in men withpre-existing ischaemic heart disease (1988) (0)
- Health related quality of life after an interventional V conservative treatment strategy for unstable angina or non-ST elevation myocardial infarction: Interim results of the RITA-3 trial (2004) (0)
- Do women and men with unstable coronary artery disease benefit from an interventional strategy? Sex differences in the RITA-3 trial (2004) (0)
- trial acute coronary syndrome based on the RITA 3 interventional strategy in non-ST-elevation The cost-effectiveness of an early (2008) (0)
- DISCOVERing treatment of type 2 diabetes in real world settings using electronic medical record databases (2015) (0)
- Identifying men at high risk of heart attacks (1986) (0)
- Angiographic findings in the of the acute catheterization and urgent intervention triage strategY (ACUITY) trial (2006) (0)
- The need for new clinical trials of old cardiovascular drugs (2022) (0)
- PREDICTORS OF DAPT USE IN PATIENTS BEYOND 1 YEAR POST MYOCARDIAL INFARCTION: INSIGHTS FROM THE TIGRIS OBSERVATIONAL STUDY (2019) (0)
- Abstract 16638: Effect of Eplerenone According to Qrs Duration and Morphology in Emphasis-HF (2014) (0)
- P493Impact of prior cerebrovascular diseases on treatment strategies and clinical outcomes after percutaneous coronary interventions (2017) (0)
- Statistical methodology for recurrent events, with application to major trials in heart failure (2013) (0)
- High density lipoprotein is not a major risk factor for ischaemic heart disease in British men (1986) (0)
- Oseltamivir for influenza – Authors' reply (2016) (0)
- Stopping the Randomized Aldactone Evaluation Study Early for Efficacy (2006) (0)
- A-34 | Renal Denervation Increases Time in Target Range Compared to Sham Control in the Presence of Antihypertension Drugs (2022) (0)
- DUAL ANTIPLATELET THERAPY (DAPT) CESSATION AND CARDIOVASCULAR RISK IN RELATION TO AGE: ANALYSIS FROM THE PARIS (PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS) REGISTRY (2019) (0)
- Drug eluting stents in patients with acute coronary syndromes undergoing percutaneous coronary intervention: The ACUITY trial (2006) (0)
- Comparison of heparin plus IIb/IIIa inhibition versus bivalirudin with or without IIb/IIIa inhibition in patients with acute coronary syndromes undergoing percutaneous coronary intervention: The ACUITY trial (2006) (0)
- Monitoring Trial Progress (2013) (0)
- Infections Up to 76 Days After Stroke Increase Disability and Death (2017) (0)
- Authors' reply (1995) (0)
- Werf, F; (2014) Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-tErm follow uP of antithrombotic management patterns In acute CORonary syndrome (2019) (0)
- RELATION OF SICKNESS ABSENCE TO METEOROLOGICAL FACTORS annual trends (0)
- PREDICTIVE VALUES OF THE IDEAL CARDIOVASCULAR HEALTH AND THE FUSTER-BEWAT SCORES FOR DETECTING SUBCLINICAL ATHEROSCLEROSIS IN HEALTHY INDIVIDUALS (2017) (0)
- Predicting mortality and morbidity in chronic heart failure independent of left ventricular systolic function: Results from the CHARM program (2004) (0)
- Abstract 11631: Risk Score for Prognosis in Patients with Systolic Heart Failure and Mild Symptoms, and the Impact of Eplerenone at Different Levels of Risk (2012) (0)
- Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction (2016) (0)
- Issues in reporting epidemiological studies - Reply (2005) (0)
- Abstract 13907: Patients With NSTEMI Are at Higher Risk, Have Worse Outcomes, but Less Intense Cardiology Follow-up 1-3 Years Post-discharge: Findings From the TIGRIS Registry (2020) (0)
- Prevention of Decline in Cognition after Stroke Trial: Final results of a factorial randomised trial of blood pressure and lipid lowering (PODCAST) (2014) (0)
- Relative Impact of MACE and Varying Definitions of Major Bleeding on Mortality: Results from the HORIZONS-AMI Trial (2008) (0)
- Comment on: Qquality of reporting of observational longitudinal research. Authors' reply (2005) (0)
- Issues in reporting epidemiological studies: Authors' reply (2005) (0)
- MULTIVESSEL VERSUS CULPRIT-ONLY PCI IN PATIENTS WITH NON-ST SEGMENT ELEVATION MYOCARDIAL INFARCTION AND MULTIVESSEL DISEASE: RESULTS FROM THE PROMETHEUS STUDY (2017) (0)
- P.08 Phase 1 open-label trial of Rycal S48168 (ARM210) for RYR1-related myopathies (2022) (0)
- 207-LB: Type 2 Diabetes and Heart Failure: Insights from the DISCOVER Study (2019) (0)
- Impact of dual antiplatelet non-adherence after percutaneous coronary intervention in patients with or without history of myocardial infarction (2021) (0)
- TCT-39 Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index: TWILIGHT-BMI Analysis (2021) (0)
- Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry. (2022) (0)
- TCT-38 Ticagrelor With and Without Aspirin in Patients With Previous Coronary Artery Bypass Graft Undergoing Percutaneous Coronary Intervention: The TWILIGHT-CABG Subanalysis (2021) (0)
- S-35-6: LONG-TERM REDUCTION IN MORNING AND NIGHTTIME BLOOD PRESSURE AFTER RENAL DENERVATION: 36-MONTH RESULTS FROM SPYRAL HTN-ON MED PILOT TRIAL (2023) (0)
- TCT-228 Prasugrel or Clopidogrel in Patients With Acute Coronary Syndromes With Multivessel Disease: Results From the PROMETHEUS Study (2021) (0)
- Response to Letter Regarding Article, “Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure” (2008) (0)
- 14. Risk factors for stroke in middle-aged men (1988) (0)
- LONG-TERM RESULTS FROM THE SPYRAL HTN-ON MED TRIAL: RENAL DENERVATION INCREASES TIME IN BLOOD PRESSURE TARGET RANGE OVER 36 MONTHS (2022) (0)
- The Effect of Internal Mammary Artery Grafts on Long-Term Clinical Outcomes After Coronary Bypass Surgery (2011) (0)
- Effect of aspirin discontinuation according to individualised patient bleeding and ischemic risks after PCI: a TWILIGHT trial sub-analysis (2022) (0)
- TCT-32 Safety and Efficacy of Biodegradable Polymer Biolimus-Eluting Stents in Patients With Non–ST-Elevation Acute Coronary Syndrome: A Pooled Analysis of GLASSY and TWILIGHT (2021) (0)
- Contrast-Induced Nephropathy Redefined; Impact of Any Acute Kidney Injury on Clinical Outcomes in Patients with ACS undergoing Angiography: Results from the ACUITY Trial (2008) (0)
- P-437: Demonstration that isotropy is a fallacy in elevated blood pressure (2001) (0)
- 761 PRASUGREL OR CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AT DIFFERENT THROMBOTIC RISK: RESULTS FROM THE PROMETHEUS STUDY (2022) (0)
- Case 19: Data Monitoring Experience in the Moxonidine Congestive Heart Failure Trial (2006) (0)
- Ticagrelor With or Without Aspirin in High-Risk Patients With Anemia Undergoing Percutaneous Coronary Intervention: a subgroup analysis of the TWILIGHT trial. (2023) (0)
- Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of glassy and twilight. (2023) (0)
- TCT-13 Ticagrelor Monotherapy in Patients With Peripheral Artery Disease Undergoing PCI (2022) (0)
- TCT-205 Incidence and clinical outcomes associated with DAPT discontinuation in complex PCI patients: From the PARIS registry. (2016) (0)
- Variation of treatment effect over time: A meta-analysis of hypertension trials (2004) (0)
- TCT-217 Predictors of Dyspnea in Patients Receiving Ticagrelor After PCI: Insights From the Twilight Trial (2021) (0)
- Long-term mortality after the blood pressure and lipid-lowering treatment in hypertensive patients: 16-year follow-up of the Anglo-Scandinavian Cardiovascular Outcomes Trial (ASCOT) Legacy study (2018) (0)
- (METOCARD-CNIC) Trial of Metoprolol in Cardioprotection During an Acute Myocardial Infarction Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: The Effect Elevation Myocardial - Effect of Early Metoprolol on Infarct Size in ST-Segment (2013) (0)
- Ticagrelor monotherapy after percutaneous coronary intervention in patients with concomitant diabetes mellitus and chronic kidney disease: a TWILIGHT substudy (2021) (0)
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial. (2023) (0)
- Title: Analysing recurrent hospitalisations in heart failure: a review of statistical methodology, with application to CHARM-Preserved Short Title: Rogers et al, Analysing recurrent hospitalisations (2015) (0)
- P1656Incremental value of interleukin-6 and C-reactive protein to the MEESSI acute heart failure risk score (2019) (0)
- P910Beware of making dose comparisons for efficacy in post-hoc analyses of achieved dose in up-titrating studies: lessons from the EMPHASIS trial (2018) (0)
- Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial (2021) (0)
- Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure (2021) (0)
- CHANGES IN WITHIN- AND BETWEEN-INDIVIDUAL BP VARIABILITY WITH BETA-BLOCKER, DIURETIC AND CALCIUM ANTAGONIST: PP.43.383 (2011) (0)
- Patterns of dual anti platelet therapy cessation in left main and proximal left anterior descending artery PCI: Results from the PARIS registry (2015) (0)
- Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis. (2023) (0)
- Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial (2020) (0)
- 203Impact of mineralocorticoid receptor antagonists on sudden cardiac death in patients with heart failure and left ventricular systolic dysfunction: a meta-analysis of three randomized controlled trials (2018) (0)
- and constitutional short stature . with growth hormone deficiency backgrounds between children histories , and social characteristics , perinatal Differences in physical (2006) (0)
- EFFECT OF PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY ON MORTALITY AND SUDDEN CARDIAC DEATH IN HEART FAILURE TREATED WITH SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS: AN ANALYSIS FROM THE EMPEROR-REDUCED TRIAL (2023) (0)
- Statistical Appraisal of Recent Clinical Cardiology Trials : ATTRACT , AUGUSTUS , CABANA , COAPT , DECLARE , and REDUCE-IT Brief title : (2019) (0)
- Health Status Across Major Subgroup of Patients with Heart Failure and Preserved Ejection Fraction. (2023) (0)
- Eplerenone versus placebo renal function stratified dose comparisons in the EMPHASIS-HF trial (2019) (0)
This paper list is powered by the following services:
Other Resources About Stuart Pocock
What Schools Are Affiliated With Stuart Pocock?
Stuart Pocock is affiliated with the following schools:
